... brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers ...
http://www.globenewswire.com/news-release/2013/06/30/557194/0/en/DGAP-News-Zyomyx-Closes-Series-2-Preferred-Financing-Round-of-12-Million-to-Enable-Launch-of-Low-Cost-Rapid-Point-of-Care-CD4-Test.html
http://www.globenewswire.com/news-release/2013/06/30/557194/0/en/DGAP-News-Zyomyx-Closes-Series-2-Preferred-Financing-Round-of-12-Million-to-Enable-Launch-of-Low-Cost-Rapid-Point-of-Care-CD4-Test.html
No comments:
Post a Comment